By Adria Calatayud


Roche Holding's Alecensa lung-cancer drug received a new approval from the U.S. Food and Drug Administration as an additional treatment for patients who have undergone surgery to remove their tumor.

The Swiss pharmaceutical giant said Friday that the approval was based on a late-stage trial that showed Alecensa reduced the risk of disease recurrence or death in patients with a type of early-stage resected nonsmall cell lung cancer.

The drug is currently approved in more than 100 countries--including the U.S.--as an initial and second-line treatment for that kind of lung cancer, the company said.


Write to Adria Calatayud at adria.calatayud@wsj.com


(END) Dow Jones Newswires

04-19-24 0129ET